Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12705521 | 0.82 | ADRA2A (0.48) | ADRA2AADRA2BADRA1AADRA2CMAP3K14 | |
| SCHEMBL12898374 | 0.81 | ADRA2A (0.47) | ADRA2AADRA2BADRA1AMAP3K14JAK2 | |
| SCHEMBL12898372 | 0.81 | ADRA2A (0.47) | ADRA2AADRA2BADRA1AMAP3K14JAK2 | |
| SCHEMBL12751055 | 0.81 | ADRA2A (0.47) | ADRA2AADRA2BADRA1AMAP3K14JAK2 | |
| SCHEMBL23505856 | 0.78 | ADRA2A (0.50) | ADRA2AADRA2BADRA1AADRA2CNOTUM | |
| SCHEMBL6026797 | 0.78 | MAP3K14 (0.51) | ADRA2AADRA2BADRA1AADRA2CNOTUM | |
| SCHEMBL23505939 | 0.76 | ADRA2A (0.51) | ADRA2AADRA2BADRA1AADRA2CNOTUM | |
| SCHEMBL3847929 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1AADRA2CNOTUM | |
| SCHEMBL31316665 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA1AADRA2CNOTUM | |
| SCHEMBL24873324 | 0.74 | ADRA2A (0.47) | ADRA2AADRA2BADRA1AADRA2CNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | ADRA2A 573/4885ADRA2B 380/4885ADRA1A 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.